Evidence map›Paper›PMID 41144745›Full record

ReviewACS infectious diseases2025

From Obscurity to Opportunity: LpxH Emerges as a Promising Antibiotic Target in the Battle against Gram-Negative Pathogens.

Patrick A Dome, C Skyler Cochrane, Hannah J Switzer, Hyejin Lee, Pyeonghwa Jeong, Jiyong Hong, Pei Zhou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patrick A DomeDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.
C Skyler CochraneDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.
Hannah J SwitzerDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.
Hyejin LeeDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.
Pyeonghwa JeongDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.ORCID 0009-0000-3796-7627
Jiyong HongDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0002-5253-0949
Pei ZhouDepartment of Chemistry, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0002-7823-3416

Funding

Discovery and validation of broadly effective LpxH inhibitors as novel therapeutics against multi-drug resistant Gram-negative pathogensR01AI139216 · NIAID · DUKE UNIVERSITY · PI ZHOU, PEI · 2019 to 2022
$1.9M
LpxH Inhibitors as Novel Therapeutics Against Multidrug-resistant EnterobacteralesR01AI189503 · NIAID · DUKE UNIVERSITY · PI Jiyong Hong, Pei Zhou · 2025 to 2026
$1.5M
Biochemistry and Structure of Lipid A EnzymesR01GM115355 · NIGMS · DUKE UNIVERSITY · PI ZHOU, PEI · 2016 to 2019
$1.2M
NIAID NIH HHS R01 AI139216NIAID NIH HHS R01 AI189503NIGMS NIH HHS R01 GM115355
6 · The paper itself

Abstract

The surging crisis of multidrug-resistant Gram-negative pathogens underscores the urgent need for antibiotics with novel mechanisms of action. A promising strategy is to target previously unexploited pathways, such as lipid A biosynthesis. Lipid A functions as the membrane anchor of lipopolysaccharide and constitutes the outer monolayer of the outer membrane of Gram-negative bacteria. LpxH, a Mn

Indexed as

Anti-Bacterial AgentsBacterial ProteinsGram-Negative BacteriaAnimalsDrug DiscoveryEnzyme InhibitorsGram-Negative Bacterial InfectionsHumansLipid AAnti-Bacterial AgentsBacterial ProteinsEnzyme InhibitorsLipid AGram-negative bacterialipid XLpxH inhibitormultidrug resistance

Identifiers

PMID41144745
PMCPMC12648303

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.